Health Canada
- Status: approved
increased dosing interval of biological therapy (increased dosing interval of biological therapy) regulatory status in Canada.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. Health Canada has authorised it.
Rigshospitalet, Denmark is the originator. The local marketing authorisation holder may differ — check the official source linked above.